AT
ATYR.US aTyr Pharma, Inc.
- Market cap
- USD 15.6M
- P/E
- -
- P/B
- 0.47x
- ROE
- -154.4%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is ATYR.US undervalued?
Graham numberThe Graham number of aTyr Pharma, Inc. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
aTyr Pharma, Inc. fundamental analysis
No fundamental analysis for aTyr Pharma, Inc. yet.
aTyr Pharma, Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About aTyr Pharma, Inc.
aTyr Pharma, Inc., a clinical stage biotechnology company, engages in the discovery and development of product candidates that translate tRNA synthetase biology into new therapies for fibrosis and inflammation in the United States. Its lead therapeutic candidate efzofitimod, a selective modulator of NRP2 that is in Phase 3 clinical trial for the treatment of pulmonary sarcoidosis; Phase 2 clinical trial to treat Sarcoidosis and systemic sclerosis- interstitial lung disease (…
Full company profileaTyr Pharma, Inc. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
aTyr Pharma, Inc. annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | - | - | - | 422K | 10.5M | 0.00 | 10.4M | 353K | 235K | 190K | 0.00 |
| Gross Profit | -900K | -713K | -746K | -13.6M | -6.84M | -1.30M | 8.69M | 353K | 235K | -1.36M | - |
| Operating Income | -59.3M | -47.1M | -32.8M | -23.0M | -15.9M | -34.0M | -46.4M | -54.9M | -67.9M | -77.6M | -54.8M |
| EBITDA | -57.0M | -46.4M | -32.1M | -21.6M | -14.6M | -32.5M | -43.6M | -47.7M | -62.5M | -72.6M | -52.4M |
| Net Income | -57.9M | -48.2M | -34.5M | -23.6M | -16.2M | -33.8M | -45.3M | -50.4M | -64.0M | -74.1M | -52.5M |
| EPS | -34 | -26 | -16 | -7.03 | -1.77 | -1.77 | -64 | -38 | -34 | -32 | -21 |
| Balance Sheet | |||||||||||
| Total Assets | 80.5M | 89.4M | 52.7M | 36.2M | 38.7M | 116M | 95.8M | 121M | 96.8M | 93.0M | 59.8M |
| Total Liabilities | 17.7M | 25.1M | 19.1M | 15.2M | 7.24M | 6.41M | 24.5M | 30.2M | 27.0M | 25.7M | 26.0M |
| Shareholders' Equity | 62.8M | 64.2M | 33.7M | 21.2M | 31.7M | 109M | 71.5M | 90.7M | 70.0M | 67.5M | 34.0M |
| Cash & Short-term Investments | 72.1M | 85.1M | 49.5M | 31.1M | 31.7M | 108M | 66.1M | 98.2M | 72.1M | 78.7M | 48.8M |
| Total Debt | 9.54M | 19.7M | 16.0M | 11.7M | 2.24M | 1.38M | 11.5M | 15.1M | 13.3M | 12.0M | 10.9M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -52.9M | -42.4M | -31.1M | -20.0M | -15.3M | -33.1M | -41.9M | -33.2M | -69.1M | -62.0M | -41.8M |
| Capital Expenditure | 600K | 1.31M | 594K | 79.0K | 202K | 192K | 1.64M | 4.22M | 65.0K | 77.0K | 341K |
| Free Cash Flow | -53.5M | -43.7M | -31.7M | -20.1M | -15.5M | -33.3M | -43.5M | -37.4M | -69.2M | -62.1M | -42.2M |
| Ratios | |||||||||||
| ROE | -92.1% | -75.0% | -102.6% | -111.4% | -51.3% | -30.9% | -63.4% | -55.6% | -91.4% | -109.8% | -154.4% |
| ROA | -71.8% | -53.9% | -65.4% | -65.2% | -41.9% | -29.2% | -47.3% | -41.8% | -66.1% | -79.7% | -87.8% |
| Net Profit Margin | - | - | - | -5,593.1% | -155.2% | - | -436.5% | -14,274.5% | -27,243.8% | -39,009.5% | - |
| Debt to Equity | 0.15x | 0.31x | 0.48x | 0.55x | 0.07x | 0.01x | 0.16x | 0.17x | 0.19x | 0.18x | 0.32x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
aTyr Pharma, Inc. dividends
aTyr Pharma, Inc. has not paid dividends in the last 9 fiscal years.
Last stock split: 1:40 on Oct 29, 2026.
Who owns aTyr Pharma, Inc.
- Insiders 0.30%
- Institutions 27.55%
- Public & others 72.15%
- Shares outstanding 2.55M
- Free float 2.45M
Top funds holding ATYR.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Abante Quant Value FI | 459K | 18.29% | 0.00% | Aug 2026 |
| Fidelity Total Market Index | 168K | 6.69% | 0.00% | Sep 2026 |
| Fidelity Series Total Market Index | 145K | 5.79% | 0.00% | Sep 2026 |
| Goldman Sachs Absolute Ret Trckr Instl | 66.0K | 2.63% | +260.80% | Jun 2026 |
| Vanguard Balanced Index Inv | 56.8K | 2.26% | 0.00% | Sep 2026 |
| Fidelity ZERO Extended Market Index | 50.9K | 2.03% | -20.76% | Sep 2026 |
| Federated Hermes Kaufmann II P | 45.9K | 1.83% | -43.37% | Sep 2026 |
| Fidelity ZERO Total Market Index | 43.1K | 1.72% | 0.00% | Sep 2026 |
| Vanguard U.S. Eq Idx £ Acc | 33.4K | 1.33% | 0.00% | Sep 2026 |
| BlackRock Diversified Equity Alpha Inst | 18.2K | 0.73% | 0.00% | Jul 2026 |
| Fidelity Flex Small Cap Index | 14.9K | 0.59% | -25.37% | Aug 2026 |
Top institutions holding ATYR.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Federated Hermes Inc | 8.51M | 8.51% | -19.03% | Jun 2026 |
| Vanguard Capital Management, LLC | 3.81M | 3.81% | -0.11% | Jun 2026 |
| Kalehua Capital Management LLC | 3.58M | 3.58% | 0.00% | Jun 2026 |
| GSA Capital Partners LLP | 3.45M | 3.45% | +105.09% | Jun 2026 |
| AQR Capital Management LLC | 2.61M | 2.61% | +426.30% | Jun 2026 |
| FMR Inc | 2.47M | 2.47% | -83.20% | Jun 2026 |
| BlackRock Inc | 1.83M | 1.83% | -71.64% | Jun 2026 |
| Jane Street Group LLC | 1.72M | 1.72% | +3,448.92% | Jun 2026 |
| UBS Group AG | 1.53M | 1.53% | -60.41% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 1.34M | 1.34% | +9.64% | Jun 2026 |
| Two Sigma Investments LLC | 1.25M | 1.25% | +8.79% | Jun 2026 |
| Citadel Advisors Llc | 1.24M | 1.24% | +2,521.94% | Jun 2026 |
| Geode Capital Management, LLC | 1.18M | 1.18% | -50.66% | Jun 2026 |
| Susquehanna International Group, LLP | 747K | 0.75% | -13.81% | Jun 2026 |
| Millennium Management LLC | 656K | 0.66% | -60.03% | Jun 2026 |
| The Goldman Sachs Group Inc | 641K | 0.64% | +126.39% | Jun 2026 |
| Vanguard Fiduciary Trust Co | 576K | 0.58% | -11.61% | Jun 2026 |
| State Street Corp | 495K | 0.50% | -71.79% | Jun 2026 |
| Marshall Wace Asset Management Ltd | 368K | 0.37% | +166.53% | Jun 2026 |
| XTX Topco Ltd | 227K | 0.23% | +103.44% | Jun 2026 |
aTyr Pharma, Inc. company profile
- Company name
- aTyr Pharma, Inc.
- Ticker
- ATYR.US
- Exchange
- USA Stocks
- Listed since
- May 7, 2015
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 58
- Fiscal year end
- December
- Address
- 10240 Sorrento Valley Road, San Diego, CA, United States, 92121
- Phone
- 858 731 8389
- Website
- atyrpharma.com
About aTyr Pharma, Inc.
aTyr Pharma, Inc., a clinical stage biotechnology company, engages in the discovery and development of product candidates that translate tRNA synthetase biology into new therapies for fibrosis and inflammation in the United States. Its lead therapeutic candidate efzofitimod, a selective modulator of NRP2 that is in Phase 3 clinical trial for the treatment of pulmonary sarcoidosis; Phase 2 clinical trial to treat Sarcoidosis and systemic sclerosis- interstitial lung disease (ILDs); and treatment of other ILDs, such as chronic hypersensitivity pneumonitis (CHP) and connective tissue disease related ILD. The company develops ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase, which is in preclinical development for the treatment of fibrosis; ATYR0750, a domain of alanyl-tRNA synthetase for the treatment of liver disorders; and develops and tests ATYR2810, the Company's monoclonal antibody that targets the neuropilin-2 (NRP2) receptor for the treatment of aggressive cancers. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. The company has a research collaboration with Albert Einstein College of Medicine to further the development and testing of ATYR2810. aTyr Pharma, Inc. was incorporated in 2005 and is headquartered in San Diego, California.
aTyr Pharma, Inc. management
5- Dr. Sanjay S. Shukla M.D., M.S.President, CEO & Director · born 1972
- Mr. Brandon YarasChief Financial Officer
- Ms. Ashlee DunstonDirector of Investor Relations & Corporate Communications
- Ms. Danielle CampbellVP of Human Resource
- Dr. Leslie Nangle Ph.D.Vice President of Research